Astria Therapeutics Inc. has released its second-quarter 2025 financial results, reporting a net loss of $33.1 million for the three months ended June 30, 2025, an increase from the $24.2 million net loss recorded during the same period the previous year. The net loss per share, basic and diluted, was $0.57 compared to $0.43 in the prior year. Research and development expenses rose to $25.9 million from $20.7 million, driven by increased navenibart expenses associated with the ALPHA-ORBIT clinical trial and higher employee costs, including stock-based compensation. General and administrative expenses increased to $9.9 million from $8.1 million, attributed to company growth and related costs. Astria's cash position as of June 30, 2025, was $259.2 million, down from $328.1 million as of December 31, 2024. However, the company expects its existing cash, along with payments from Kaken Pharmaceutical and anticipated reimbursements, to fund operations into 2028. Key business updates include the ongoing ALPHA-ORBIT Phase 3 trial of navenibart (STAR-0215) for hereditary angioedema, with topline data expected in early 2027, and the anticipated Q3 2025 results from the Phase 1a trial of STAR-0310 for atopic dermatitis.